Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Adial acquires Azora Therapeutics for $64 million

PUBLIC · ADILAug 17, 2026•about 3 hours ago

Acquiring Company

Adial Pharmaceuticals

Acquired Company

Azora Therapeutics

Glen Allen

EncinoBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalHealthcare

Description

Adial Pharmaceuticals has completed its acquisition of Azora Therapeutics, expanding its portfolio with the addition of AT177, a treatment for ulcerative colitis. This acquisition is valued as part of a larger private placement of up to $64 million. Adial posted a significant net loss for the quarter but continues to advance its pipeline, including plans for future clinical trials.

Company Information

Company

Adial Pharmaceuticals

Location

Glen Allen, Virginia, United States

About

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARDTM pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

Don't miss Adial Pharmaceuticals's next move

Get an email the moment Adial Pharmaceuticals makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Adial Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Azora Therapeutics?

Azora Therapeutics was acquired by Adial Pharmaceuticals, based in Glen Allen. The deal was reported on August 17, 2026. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. Adial Pharmaceuticals is publicly traded (ADIL) and operates in Biotechnology.

When did Adial Pharmaceuticals acquire Azora Therapeutics?

Adial Pharmaceuticals's acquisition of Azora Therapeutics was reported on August 17, 2026. Adial Pharmaceuticals has completed its acquisition of Azora Therapeutics, expanding its portfolio with the addition of AT177, a treatment for ulcerative colitis. This acquisition is valued as part of a larger private placement of up to $64 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Azora Therapeutics do?

Azora is clinical stage pharmaceutical company developing novel therapies for serious inflammatory diseases like hidradenitis suppurativa (HS) and ulcerative colitis (UC). It is privately held, operating in Healthcare, and is based in Encino.